Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

Overview
Date Founded

1987

Headquarters

11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037

Type of Company

Public

Employees (Worldwide)

116

Industries

Retail: Drug Stores
Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Ligand Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

President & Chief Operating Officer

Executive Vice President, Finance & Chief Financial Officer

Senior Vice President, General Counsel & Secretary

Senior Vice President, Human Resources

Senior Vice President, Biology & Scientific Affairs

Senior Vice President, Technical Operations

Vice President

Vice President, New Product Development

Vice President, Antibody Technologies

Board of Directors

Chief Scientific Officer & Director at ActivX Biosciences, Inc.

Managing Director at Cowen Healthcare Royalty Management LLC

Partner & Health Care Portfolio Manager at Knott Partners LP

President & Chief Executive Officer at Gordon Research Conference on Nonlinear Optics & Lasers

Former Chief Accounting Officer at OncoMed Pharmaceuticals, Inc.

Founder & Managing General Partner at JALAA Equities LP

Co-Founder at Hybritech Incorporated

Paths to Ligand Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Ligand Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Cardinal Capital Management engages in a buy and hold investment strategy that focuses on investments in domestic micro-cap, small-cap and SMID-cap value equities. The firm buys securities and holds them for a relatively long period of time, regardless of short-term factors such as fluctuations in the market or volatility of the stock price. From time to time, however, Cardinal may hold securities for significantly shorter periods of time. The firm searches for investment opportunities within inefficient market niches with emphasis on companies emerging from bankruptcy or corporate restructurings such as spin-offs. They seek to identify companies that are not yet well known or are underfollowed, and to develop opinions on out-of-favor companies businesses. Cardinal also investigates corporate events that often signal undervaluation by tracking large share repurchase activity, significant insider buying and announcements that companies are pursuing strategic alternatives. ^

Details Hidden

Conestoga Capital Advisors (CCA) generally uses an investment process that is based on fundamental business and credit analysis; capital structure and liquidation analysis, a review of all legal documentation surrounding an issuer's securities; and identification of an investment catalyst. In making investment decisions, the firm relies on internally generated research, derived from annual reports, prospectuses, filings with the SEC, corporate press releases, inspections of corporate activities, conversations with the firm and/or competitors, financial newspapers, magazines and other sources. They may also use research materials prepared by others in making an investment decision. During the research process, CCA makes an assessment of the quality of the security in question by examining, among other things, financial metrics of the relevant company, the integrity and strategic vision of the management team and the ability to execute such strategy, as well as the attractiveness and risks of the company's industry. The firm reviews companies that meet its criteria, and if according to their analysis, a company has the potential to appreciate at least 100% over a three-to-five year period they will make a decision to buy the security. Client portfolios are fully invested and diversified across industries.

Details Hidden

Elk Creek Partners specialize in making growth-oriented investments in publicly-traded stocks of small- and medium-sized companies. The firm offers investment advisory services for specific strategies, including Small-Cap Growth, Mid-Cap Growth and SMID-Cap Growth. Elk Creek Partners works with clients to establish investment objectives based on their unique circumstances. The key elements of the firm's investment approach are growth company identification, fundamental research, valuation analysis, and portfolio construction.The firm's Small-Cap Growth strategy is based on a fundamental, stock-by-stock approach. The portfolio is concentrated in stocks purchased with a market-cap generally of $500 million to $5 billion and with portfolio characteristics similar to the Russell 2000 Growth Index. They target companies with sustained growth and which have products and/or services that are market-share takers.Elk Creek's SMID-Cap Growth strategy is a direct extension of the Small-Cap strategy. The SMID Cap Growth strategy concentrates in stocks with a market-cap of $1 billion to $10 billion and with portfolio characteristics similar to the Russell 2500 Growth Index. The process implemented in the SMID-Cap strategy is the same as the Small-Cap strategy in both buying and selling individual stocks.The firm's Mid-Cap Growth strategy is a direct extension of the Small- and SMID-Cap Growth strategies. The Mid-Cap Growth strategy concentrates in stocks with a market-cap of $2 billion to $12 billion and with portfolio characteristics similar to the Russell Mid-Cap Growth Index. The process implemented in the Mid-Cap strategy is the same as the Small-Cap strategy in both buying and selling individual stocks. ^

Recent Transactions
Details Hidden

Ligand Pharmaceuticals, Inc. purchases Ab Initio Biotherapeutics, Inc.

Details Hidden

Ligand Pharmaceuticals, Inc. purchases Vernalis Plc

Details Hidden

Ligand Pharmaceuticals, Inc. purchases Crystal Bioscience, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onLigand Pharmaceuticals, Inc. purchases Pharmacopeia LLC

Legal Advisor

Advised onLigand Pharmaceuticals, Inc. purchases CyDex Pharmaceuticals, Inc.

Investment Advisor

Advised onLigand Pharmaceuticals, Inc. purchases Seragen, Inc.

Legal Advisor

Advised onLigand Pharmaceuticals, Inc. purchases Crystal Bioscience, Inc.

Attorney

Advised onLigand Pharmaceuticals, Inc. purchases Crystal Bioscience, Inc.

Lender

Advised onLigand Pharmaceuticals, Inc. purchases CyDex Pharmaceuticals, Inc.

Advisors & Consultants
Legal Advisor

Former Office Managing Partner at McKenna Long & Aldridge LLP

Legal Advisor

Shareholder at Stradling, Yocca Carlson & Rauth PC

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Key Stats and Financials As of 2018
Market Capitalization
$2.29B
Total Enterprise Value
$3.14B
Earnings Per Share
$5.96
Revenue
$251M
Net Profit
$143M
Total Equity
$561M
Total Debt
$636M
Three Year Compounded Annual Growth Rate Of Revenue
51.78%
Five Year Compounded Annual Growth Rate Of Revenue
38.71%
Enterprise Value Sales
12.47x
TEVNet Income
21.87x
Debt TEV
0.2x
EBITDAMargin
71.75%
Enterprise Value EBITDAOperating
17.38x
EBITDA
$180M
Non-Profit Donations & Grants
$100 - $999
2009
$5,000 - $10K
2004
Political Donations
$250
1998
$1,000
1998
Suppliers
Hovione Farmaciência SA Wholesale: Consumer Non-Durables/Sundries | Loures, LI

Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal.

Sangamo Therapeutics, Inc. Pharmaceuticals | Richmond, CA

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Sangamo was founded in 1995, went public in 2000, and trades on the Nasdaq Global Market (SGMO). We are located in Richmond, California, in the Bay Area, the birthplace of biotechnology. We are intimately involved in our community through partnerships with academic institutions, relationships with non-profit organizations and ties to advocacy organizations aligned with improving the quality of life for patients with unmet medical needs within our strategic vision.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ligand Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ligand Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Ligand Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/ligand-pharmaceuticals-inc-18382
  • https://relationshipscience.com/organization/ligand-pharmaceuticals-inc-18382